EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer

Journal:

Journal of Clinical Investigation

Published:

2026-04-07

DOI:

10.1172/jci201090

Affiliations:

7

Authors:

16

Go to article

Institutions	Authors	Share
MOE Key Laboratory of Metabolism and Molecular Medicine, Fudan University, China	4.000000	0.25
Shanghai Medical College (SHMC), Fudan University, China	3.166667	0.20
Fudan University Shanghai Cancer Center (FUSCC), China	3.166667	0.20
Biokin Pharma, China	3.000000	0.19
Changhai Hospital, SMMU, China	2.666667	0.17

Interested in Oncology and Carcinogenesis?